Eline van Overbeeke

Health Economics and Outcomes Research Manager @pfizer. Opinions are my own.

[PREFER: patient preferences @IMI_PREFER]

For rare diseases, finding a way to include the #patient perspective in decision-making can be crucial. With answers from 117 people with #haemophilia, we can now present results about their preferences for #GeneTherapy

https://t.co/QKnWnHVqLL #PatientPreferences @van_overbeeke

[PREFER: patient preferences @IMI_PREFER]

Webinar recording available! @van_overbeeke & colleagues investigated #haemophilia #patients’ preferences for #GeneTherapies. Learn about how the preference study was designed, what the results were & what the impact might be!

https://t.co/a6fzfPoeat

#PatientPreferences @IMI_JU

[PREFER: patient preferences @IMI_PREFER]

Join us at 14:00 CEST when we talk a study that has investigated #haemophilia #patients’ preferences for #GeneTherapies. Learn how it was designed, what the results were & what the impact might be in today's webinar!

https://t.co/CvPaW9pRWm

@IMI_JU #PatientPreferences

[PREFER: patient preferences @IMI_PREFER]

Join our September 17 webinar on #haemophilia #patients preferences for #GeneTherapy with speakers @van_overbeeke, Isabelle Huys & Brett Hauber!

Read about it & sign up here: https://t.co/nHx9RwAcId…

#PatientPreferences @IMI_JU

[EAHAD @EAHADnews]

New #Haemophilia article on patient preferences for #GeneTherapy shows the value of preference heterogeneity and patient education on novel treatment acceptance. Open Access⤵️
https://t.co/0OETmBCvZH

[PREFER: patient preferences @IMI_PREFER]

.@van_overbeeke et al asked 117 #haemophilia patients about their preferences for #GeneTherapy! It turns out, their preferences vary greatly. And that informing #patients can facilitate acceptance!

https://t.co/SamChb19S5 @eahad @IMI_JU #PatientPreferences

[PREFER: patient preferences @IMI_PREFER]

Remember to register for our #webinar tomorrow to learn all about #patient involvement in patient preference studies! https://t.co/scvNohi7SU

Or discover other @IMI_PREFER webinars here:
https://t.co/IslaEvGcYF

#PatientPreferences

[Muscular Dystrophy UK @MDUK_News]

Involving patients from an early stage when designing patient preference studies (what aspects of different treatments really matter) is something that @IMI_PREFER believes has huge benefits. Find out more about why in their webinar on 11 June >> https://t.co/ythbgt2zBO

[PREFER: patient preferences @IMI_PREFER]

#Patient, #regulator, #HTA, #academic or working in #pharma and free on 15-16 June? Why not join the PREFER/@DrugInfoAssn workshop on valuable decision-making through #PatientPreference studies, free of charge! 👉 https://t.co/3EhBSNN394

[PREFER: patient preferences @IMI_PREFER]

Looking for some weekend reading? Have a look at this paper about #PatientPreferences for #GeneTherapy in haemophilia by @van_overbeeke et al!

@FrontMedicine

https://t.co/kmEaF7T0nj

[Eline van Overbeeke @van_overbeeke]

Proud to have contributed to this great dicussion.
Thanks again for the opportunity @wfhemophilia.
#GeneTherapy #hemophilia #paving

[WFH @wfhemophilia]

In March, the WFH held the first #WFHGeneTherapy round table session of 2021. At this closed meeting healthcare professionals met to discuss the future direction of #genetherapy in #hemophilia. Learn more about what they discussed here: https://t.co/1byH2GHsN9

[PREFER: patient preferences @IMI_PREFER]

What are the research needs for #HTA today and tomorrow? And how can we ensure HTA and payer decision making includes the #patient perspective?

At the @EUnetHTA forum today? Don't miss PREFER's Irina Cleemput from @KCEfgov in the 2PM session.

https://t.co/DPAHveySwP

[PREFER: patient preferences @IMI_PREFER]

What is a #PatientPreference & what is the value in medical product decision-making? Join us on 26 April at 16:30 CEST to discuss the value of #patient preferences in the #MedicalProduct life cycle!

👉 https://t.co/uUl1qENx8o

[Ksehmi @Ksehmi5]

Great to work with the @IMI_PREFER on access to innovative innovative medicines issues. This paper sets the framework in #PatientPreferences to Assess Value IN Gene Therapies: Protocol Development for the PAVING Study in Hemophilia. https://t.co/XyfUQhSObW

[PREFER: patient preferences @IMI_PREFER]

PREFER researchers have designed the very first patient preference study about what people with #haemophilia think about #GeneTherapies being brought to market.

https://t.co/3UNB2HVwqc #PatientPreferences @van_overbeeke

[Frontiers - Medicine @FrontMedicine]

New Research: Patient Preferences to Assess Value IN Gene Therapies: Protocol Development for the PAVING Study in Hemophilia: Introduction: Gene therapies are innovative therapies that are increasingly being developed.… https://t.co/uF3vspVmXN #medicalcare #clinical #pathology

[Eline van Overbeeke @van_overbeeke]

Super excited to share our newest publication on how to measures patient preferences for gene therapies @IMI_PREFER @AHVH_Belgium

[PREFER: patient preferences @IMI_PREFER]

JUST PUBLISHED | #PatientPreferences to Assess Value IN #GeneTherapies: Protocol Development for the PAVING Study in #Hemophilia

https://t.co/lqcLjC8HwI @van_overbeeke
@FrontMedicine

[PREFER: patient preferences @IMI_PREFER]

JUST PUBLISHED | #PatientPreferences to Assess Value IN #GeneTherapies: Protocol Development for the PAVING Study in #Hemophilia

https://t.co/lqcLjC8HwI @van_overbeeke
@FrontMedicine

[Patient Journal @PatientJournal]

First issue of 2021 of @PatientJournal now available: https://t.co/puHSquTojo
Lots of great articles including: participant understanding in DCE (@aliepea), conceptual model of CLL to understand pt experience (@tobyeyre82), and the use of pt preferences in HTA (@van_overbeeke)

[PREFER: patient preferences @IMI_PREFER]

#GeneTherapy can be an effective treatment for #haemophilia. But what do the patients think? Check out this open access paper from one of the #PREFERCaseStudies by @van_overbeeke et al 👉 https://t.co/ijFWvETnR4